Scilex Holding Co (SCLX)
0.9054
+0.04
(+4.07%)
USD |
NASDAQ |
May 17, 16:00
0.938
+0.03
(+3.60%)
After-Hours: 20:00
Scilex Cash from Financing (Quarterly): -11.20M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -11.20M |
| December 31, 2023 | 8.306M |
| September 30, 2023 | -38.89M |
| June 30, 2023 | 43.54M |
| March 31, 2023 | 10.63M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.426M |
| September 30, 2022 | -6.868M |
| June 30, 2022 | -12.35M |
| March 31, 2022 | 39.96M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-38.89M
Minimum
Sep 2023
43.54M
Maximum
Jun 2023
3.729M
Average
0.426M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Sorrento Therapeutics Inc | 88.81M |
| Adial Pharmaceuticals Inc | 3.384M |
| Precision BioSciences Inc | 40.10M |
| Humacyte Inc | 62.80M |
| Perspective Therapeutics Inc | 166.33M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 9.391M |
| Cash from Investing (Quarterly) | -0.15M |
| Free Cash Flow | -4.052M |
| Free Cash Flow Per Share (Quarterly) | 0.0902 |
| Free Cash Flow to Equity (Quarterly) | 25.46M |
| Free Cash Flow to Firm (Quarterly) | 9.772M |
| Free Cash Flow Yield | -3.74% |